UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of ~~report~~Report (Date of earliest event reported) May 10, 2011

INSPIRE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in ~~Charter~~its charter)

Delaware	~~000~~001-31135	04-3209022
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
8081 Arco Corporate Drive, Suite 400, Raleigh, North Carolina		~~27703-8466~~27617
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code (919) 941-9777

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

OnAs previously ~~May 10,~~reported ~~2011,~~by Inspire Pharmaceuticals, Inc. ~~issued~~(the a“Company”), ~~press~~following ~~release~~the ~~announcing~~Company’s ~~summary~~announcement ~~financial~~that ~~results~~it ~~for~~had entered into an Agreement and Plan of Merger (the ~~fiscal~~“Merger ~~quarter~~Agreement”) ~~ended~~dated ~~March~~as of April 315, 2011 with Merck & Co., ~~The~~Inc. ~~press~~(“Merck”) ~~release~~and ~~issued~~Monarch Transaction Corp., a wholly-owned subsidiary of Merck (“Monarch”), a purported class action lawsuit was filed in ~~connection~~the United States District Court for the Eastern District of North ~~with~~Carolina, ~~such~~against ~~announcement~~the isCompany, ~~attached~~the ~~hereto~~Company’s asBoard ~~Exhibit~~of Directors, Merck 99and Monarch under the caption Norris Foster, et al.1 v. George Abercrombie, et al., No. 5:11-CV-00180.

~~The~~On ~~information~~May 10, in2011, ~~this~~the ~~Current~~United ~~Report~~States onDistrict ~~Form~~Court ~~8-K,~~for ~~including~~ the Eastern District of North Carolina denied plaintiffs’ request for a ~~accompanying~~preliminary ~~exhibit,~~injunction isin ~~being~~connection ~~furnished~~with ~~and~~the ~~shall~~purported ~~not~~class beaction ~~deemed~~suit ~~“filed”~~that ~~for~~would ~~purposes~~have ofdelayed ~~Section 18~~or ofprevented the ~~Securities~~proposed ~~Exchange~~sale ~~Act~~ of ~~1934,~~the asCompany ~~amended~~and (the ~~“Exchange~~tender ~~Act”),~~offer orin ~~otherwise~~connection ~~subject~~with to the ~~liabilities~~Merger Agreement. As a result of ~~that section,~~the ~~nor~~Court’s ~~shall~~denial, there itis beno ~~deemed~~pending ~~incorporated~~litigation bythat ~~reference~~would inreasonably ~~any~~be ~~filing~~expected ~~under~~to prevent the ~~Securities~~consummation ~~Act~~of the merger of ~~1933,~~Monarch aswith ~~amended,~~and orinto the ~~Exchange Act~~Company, ~~except~~subject asto ~~expressly~~the ~~set~~satisfaction ~~forth~~of bythe ~~specific~~terms ~~reference~~and conditions set forth in ~~such~~the ~~filing~~Merger Agreement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.		Description
99.1		Press release dated May 10, 2011.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Inspire Pharmaceuticals, Inc.

By:		/s/ Joseph M. Spagnardi
		Joseph M. Spagnardi,
		Senior Vice President, General Counsel
		and Secretary

Dated: May 1011, 2011

EXHIBIT INDEX

No.		Description
99.1		Press release dated May 10, 2011.

Filing Compare · INSPIRE PHARMACEUTICALS INC